The first Phase III study of Novartis AG’s potential treatment option for chronic myeloid leukemia, asciminib (ABL001), has met its primary endpoint, topline data show.
The 234-patient ASCEMBL trial showed a significantly better major molecular response (MMR) rate at 24 weeks with asciminib (ABL001) versus Pfizer’s BCR-ABL and src tyrosine kinase inhibitor, Bosulif (bosutinib)